Form 4: Spero Therapeutics CEO Sath Shukla Reports Stock Transactions
SEC Form 4 Filing
Sath Shukla, CEO of Spero Therapeutics, reports the acquisition and disposal of common stock related to restricted stock units (RSUs) vesting.
Summary
- Sath Shukla, the CEO and President of Spero Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On February 3, 2025, Shukla acquired 751,407 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.
- On February 5, 2025, Shukla disposed of shares of common stock to cover tax withholding obligations related to RSU vesting.
- Specifically, 6,139 shares were sold at $0.78, followed by 42,786 shares at $0.78, and then 106,408 shares at $0.78.
- Following these transactions, Shukla directly owns 1,736,883 shares of Spero Therapeutics common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports stock transactions related to executive compensation. It doesn't inherently indicate positive or negative news about the company's performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can be informative for investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased number of shares being traded in the market.
Key Dates
| Date | Description |
|---|---|
| 02/01/2022 | Date of RSU grant related to some of the sold shares. |
| 02/01/2023 | Date of RSU grant related to some of the sold shares. |
| 02/01/2024 | Date of RSU grant related to some of the sold shares. |
| 02/03/2025 | Date of acquisition of 751,407 shares through RSU vesting. |
| 02/05/2025 | Date of sale of 155,333 shares to cover tax obligations. |
| 02/03/2026 | First vesting date of the RSUs acquired on February 3, 2025. |
Keywords
Form 4, Spero Therapeutics, Sath Shukla, Stock Transactions, RSU, Beneficial Ownership, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.